Fully Human Monoclonal Antibodies that Broadly Neutralize SARS-COV-2

Patent metadata

Field	Value
Publication number	US-2024018217-A1
Application number	US-202318344680-A
Country	US
Kind code	A1
Filing date	Jun 29, 2023
Priority date	Jun 29, 2022
Publication date	Jan 18, 2024
Grant date	—

Abstract

The present invention includes antibodies and antigen-binding fragments thereof that specifically bind a SARS-CoV-2 antigen and are in certain embodiments capable of neutralizing a SARS-CoV-2 infection. Polynucleotides encoding an antibody or an antigen-binding fragment, vectors and host cells that comprise a polynucleotide and pharmaceutical compositions are also included in this invention. Also described herein are methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to diagnose, prevent or treat a SARS-CoV-2 infection.

First claim

1 . A method for treating a glioblastoma in a human subject consisting essentially:
identifying the human subject in need of treatment of a glioblastoma, wherein the human is no longer responsive to at least one of chemotherapy, surgery, or radiation therapy as a result of increased ceramide production in the glioblastoma cell; and administering to the human subject no longer responsive to at least one of chemotherapy, surgery, or radiation therapy, a therapeutically effective amount of a composition consisting of: an amount of a curcumin or curcuminoids in one or more liposomes, or curcumin or curcuminoids and empty liposomes administered prior to, concomitantly, or after administration of the curcumin or curcuminoids, that is effective for treating the glioblastoma, wherein the liposomal curcumin or curcuminoids, or empty liposomes, eliminate the QT prolongation caused by the curcumin or curcuminoids; and at least one chemotherapeutic agent, wherein the amount of the curcumin or curcuminoids is synergistic with the at least one chemotherapeutic agent to treat the glioblastoma, wherein the at least one chemotherapeutic agent is selected from at least one of etoposide, carmustine, lomustine, ceramide and phosphorylcholine that is no longer responsive to at least one of chemotherapy, surgery, or radiation therapy, wherein the glioblastoma cells are sensitized to an agent to which they have become refractory as a result of the increased ceramide production in the glioblastoma cell.

2 . (canceled)

3 . The method of claim 1 , wherein the QT prolongation is LQTS.

4 . The method of claim 3 , wherein the liposomal curcumin or curcuminoids, or empty liposomes are provided intravenously.

5 . The method of claim 1 , wherein the composition increases ceramide production of the glioblastoma cell.

6 . The method of claim 1 , wherein the composition increases phosphorylcholine production of the glioblastoma cell.

7 . The method of claim 1 , wherein the glioblastoma cells are sensitized to an agent to which they have become refractory as a result of increased ceramide production in the glioblastoma cell.

8 . The method of claim 1 , wherein the glioblastoma cells are sensitized to an agent to which they have become refractory as a result of increased phosphorylcholine production in the glioblastoma cell.

9 . A method for treating a glioblastoma in a human subject comprising the steps of:
identifying the human subject in need of treatment of a glioblastoma, wherein the human is no longer responsive to at least one of chemotherapy, surgery, or radiation therapy as a result of increased ceramide production in the glioblastoma cell; and concurrently administering to the human subject no longer responsive to at least one of chemotherapy, surgery, or radiation therapy, a therapeutically effective amount of a composition consisting of: an amount of a curcumin or curcuminoids in one or more liposomes, or curcumin or curcuminoids and empty liposomes; an amount of one or more liposomes or empty liposomes prior to, concomitantly, or after administration of the curcumin or curcuminoids, that is effective for treating the glioblastoma, wherein the liposomal curcumin or curcuminoids, or the empty liposomes that eliminate the QT prolongation caused by the curcumin or curcuminoids; and administering at least one chemotherapeutic agent, wherein the amount of the curcumin or curcuminoids is synergistic with the at least one chemotherapeutic agent to treat the glioblastoma, selected from at least one of etoposide, carmustine, lomustine, ceramide and phosphorylcholine to treat the glioblastoma that is no longer responsive to at least one of chemotherapy, surgery, or radiation therapy, wherein the glioblastoma cells are sensitized to an agent to which they have become refractory as a result of the increased ceramide production in the glioblastoma cell.

10 . The method of claim 9 , wherein the QT prolongation is LQTS.

11 . The method of claim 9 , wherein the liposomal curcumin or curcuminoids, or empty liposomes are provided intravenously.

12 . The method of claim 9 , wherein the composition increases ceramide production of the glioblastoma cell.

13 . The method of claim 9 , wherein the composition increases phosphorylcholine production of the glioblastoma cell.

14 . The method of claim 9 , wherein the glioblastoma cells are sensitized to an agent to which they have become refractory as a result of increased ceramide production in the glioblastoma cell.

15 . The method of claim 9 , wherein the glioblastoma cells are sensitized to an agent to which they have become refractory as a result of increased phosphorylcholine production in the glioblastoma cell.

16 .- 20 . (canceled)

Assignees

• Oklahoma Med Res Found

Inventors

• Smith Kenneth

Classifications

• C07K16/104 Primary

  Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2] · CPC title

• C07K16/1003 Primary

  Chemistry & Metallurgy · mapped topic

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K39/42

  viral · CPC title

• A61K49/0058

  Antibodies · CPC title